Biotech & Semiconductor Stocks See Significant Market Declines

Font: Financial Modeling Prep  • Sep 24, 2026

Market Declines: Key Insights from Biotechnology and Semiconductor Sectors

• Trio-Tech International (NASDAQ: TRT) experienced a significant drop despite strong revenue growth driven by AI and automotive semiconductor demand.
• Artelo Biosciences, Inc. (NASDAQ: ARTL) declined sharply after filing a provisional patent application related to its obesity compound.
• Jaguar Health, Inc. (NASDAQ: JAGX) faced a downturn tied to equity dilution concerns following a debt-for-equity exchange.

The market saw significant declines today, with notable moves in the biotechnology and semiconductor sectors. Shares of Trio-Tech International (NASDAQ: TRT) fell about 36.6% to $7.26 on high trading volume of about 2.86 million shares. The decline came despite the company reporting 72% revenue growth for fiscal 2026, driven by continued demand from AI and automotive semiconductor markets.

Artelo Biosciences, Inc. (NASDAQ: ARTL) declined about 29.5% to $5.17. The clinical-stage pharmaceutical company recently filed a provisional patent application for the use of ART27.13 in obesity, both as a standalone treatment and in combination with GLP-1 receptor agonists. The compound showed meaningful weight-loss results in nonclinical studies, making the sharp stock decline notable despite the positive development update.

Shares of Jaguar Health, Inc. (NASDAQ: JAGX) fell about 21% to roughly $7.06. The drop was linked to concerns about equity dilution after the company entered into debt-for-equity exchange agreements. Equity dilution can occur when a company issues new shares, potentially reducing the ownership percentage and value of existing shares.

Scribe Therapeutics Inc. (NASDAQ: SCTX) saw its shares decline about 18% to $21.61. The company recently announced positive updates, including the initiation of a Phase 1 trial for STX-1150 and approximately $155.5 million in gross proceeds from its IPO and concurrent private placement. The funding is expected to support operations into the first half of 2029.

The Leverage Shares 2X Long ARM Daily ETF (NASDAQ: ARMG) also dropped about 15.8% to $23.86. Because this ETF seeks to deliver twice the daily performance of Arm Holdings, its movement reflects amplified exposure to the underlying ARM stock.

In summary, today’s market losers present a mixed picture. Jaguar Health, Inc. (NASDAQ: JAGX) declined on dilution concerns, while Trio-Tech International (NASDAQ: TRT) and Artelo Biosciences, Inc. (NASDAQ: ARTL) fell despite positive company updates. This suggests broader market sentiment and short-term trading pressure may be influencing investor decisions beyond individual company fundamentals.